Angela Puddy

Angela Puddy serves as a key procurement professional within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate the development of medical countermeasures, diagnostic tools, and high-containment laboratory infrastructure. She manages a portfolio of complex acquisitions centered on advanced biomedical research capabilities, including analytical instrumentation, biosafety equipment, and specialized biological manufacturing services. Her work directly enables NIAID’s response to emerging infectious and immunologic threats by ensuring timely access to mission-critical technologies and laboratory systems. She typically handles competitive sealed bidding and negotiated procurements under FAR and HHS acquisition regulations, with a focus on scientific and technical requirements tied to biosafety level 3 and 4 operations. Puddy maintains consistent contracting relationships with Quality Biological, Inc., a leading provider of reference reagents and biological materials, and GENOMIC LABS LTD, a specialized supplier of genomic analysis tools and sequencing technologies. These partnerships reflect a preference for vendors with proven expertise in high-purity biological products and precision diagnostic platforms. Her contracting approach emphasizes vendor reliability, regulatory compliance, and technical validation, often requiring adherence to cGMP, ISO, and CLIA standards. She engages with a narrow cohort of highly specialized contractors, prioritizing technical capability over volume. Puddy’s procurement portfolio is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects NIAID’s need for specialized, high-performance solutions that require technical depth beyond the capacity of most small businesses, rather than a lack of commitment to socioeconomic programs. Her approach aligns with mission-critical timelines and regulatory constraints that prioritize performance and compliance over socioeconomic preferences. Her primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing) and 325414 (biological product manufacturing), with significant activity in electronic equipment maintenance (811210) and in-vitro diagnostic substance production (325413). She routinely acquires next-generation sequencers, biosafety cabinets, cryogenic storage systems, and validated reagents for pathogen research, demonstrating deep technical fluency in high-containment biomedical procurement.